Plains GP Holdings (PAGP) receives a Strong Buy rating with a fair value target of $33.40 per share, representing a 19% increase from current prices. The company's leverage has significantly decreased to 3.3x adjusted EBITDA, supported by growth in Permian volumes and rising distributions. Despite recent stock gains, the yield compression has lagged behind balance sheet improvements, suggesting potential for a yield increase to 5.00%, which could drive a total return near 25% within a year. Risks include possible declines in Permian volumes, sustained high yields, and the challenge of refinancing $8.44 billion in debt at higher interest rates.
Plains GP Holdings is the subject of recent analysis with a Strong Buy rating and a target price of $33.40 per share. For readers following the energy sector, here is Pluang's market snapshot as of Sep 15, 2026 17:23 WIB: out of 30 priced US energy stocks, 21 rose and 8 fell today. Notable movers include Valero Energy Corporation at USD 385.83 (+0.75%), Occidental Petroleum Corporation at USD 62.20 (+0.68%), and Marathon Petroleum Corp at USD 399.00 (+0.64%).
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
